ObsEva SA / ObsEva Starts Phase 3 Clinical Program for Nolasiban in ART . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.
- IMPLANT2 study to confirm efficacy and safety of novel, oral oxytocin receptor antagonist in infertile patients undergoing embryo transfer as part of assisted reproductive technology (ART) -
Geneva, Switzerland - 07 March 2017 - ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical com
RelSci News & Alerts gets you: